Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.

Sobral-Leite M, Van de Vijver K, Michaut M, van der Linden R, Hooijer GKJ, Horlings HM, Severson TM, Mulligan AM, Weerasooriya N, Sanders J, Glas AM, Wehkamp D, Mittempergher L, Kersten K, Cimino-Mathews A, Peters D, Hooijberg E, Broeks A, van de Vijver MJ, Bernards R, Andrulis IL, Kok M, de Visser KE, Schmidt MK.

Oncoimmunology. 2018 Sep 11;7(12):e1509820. doi: 10.1080/2162402X.2018.1509820. eCollection 2018.

PMID:
30524905
2.

Immune regulation of metastasis: mechanistic insights and therapeutic opportunities.

Blomberg OS, Spagnuolo L, de Visser KE.

Dis Model Mech. 2018 Oct 24;11(10). pii: dmm036236. doi: 10.1242/dmm.036236. Review.

3.

Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape.

Wellenstein MD, de Visser KE.

Immunity. 2018 Mar 20;48(3):399-416. doi: 10.1016/j.immuni.2018.03.004. Review.

PMID:
29562192
4.

The adaptive immune system promotes initiation of prostate carcinogenesis in a human c-Myc transgenic mouse model.

Melis MHM, Nevedomskaya E, van Burgsteden J, Cioni B, van Zeeburg HJT, Song JY, Zevenhoven J, Hawinkels LJAC, de Visser KE, Bergman AM.

Oncotarget. 2017 Sep 28;8(55):93867-93877. doi: 10.18632/oncotarget.21305. eCollection 2017 Nov 7.

5.

Neutrophils take a round-trip.

Garner H, de Visser KE.

Science. 2017 Oct 6;358(6359):42-43. doi: 10.1126/science.aap8361. No abstract available.

PMID:
28983037
6.

Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages.

Kersten K, Coffelt SB, Hoogstraat M, Verstegen NJM, Vrijland K, Ciampricotti M, Doornebal CW, Hau CS, Wellenstein MD, Salvagno C, Doshi P, Lips EH, Wessels LFA, de Visser KE.

Oncoimmunology. 2017 Jun 19;6(8):e1334744. doi: 10.1080/2162402X.2017.1334744. eCollection 2017.

7.

Genetically engineered mouse models in oncology research and cancer medicine.

Kersten K, de Visser KE, van Miltenburg MH, Jonkers J.

EMBO Mol Med. 2017 Feb;9(2):137-153. doi: 10.15252/emmm.201606857. Review.

8.
9.

Neutrophils in cancer: neutral no more.

Coffelt SB, Wellenstein MD, de Visser KE.

Nat Rev Cancer. 2016 Jul;16(7):431-46. doi: 10.1038/nrc.2016.52. Epub 2016 Jun 10. Review.

PMID:
27282249
10.

CANCER. How neutrophils promote metastasis.

Tüting T, de Visser KE.

Science. 2016 Apr 8;352(6282):145-6. doi: 10.1126/science.aaf7300. No abstract available.

PMID:
27124439
11.

Revving Up Dendritic Cells while Braking PD-L1 to Jump-Start the Cancer-Immunity Cycle Motor.

Coffelt SB, de Visser KE.

Immunity. 2016 Apr 19;44(4):722-4. doi: 10.1016/j.immuni.2016.03.014.

12.

Systemic inflammation: Cancer's long-distance reach to maximize metastasis.

Coffelt SB, de Visser KE.

Oncoimmunology. 2015 Aug 17;5(2):e1075694. eCollection 2016 Feb.

13.

Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy.

Kersten K, Salvagno C, de Visser KE.

Front Immunol. 2015 Oct 7;6:516. doi: 10.3389/fimmu.2015.00516. eCollection 2015. Review.

14.

Immune-mediated mechanisms influencing the efficacy of anticancer therapies.

Coffelt SB, de Visser KE.

Trends Immunol. 2015 Apr;36(4):198-216. doi: 10.1016/j.it.2015.02.006. Review.

PMID:
25857662
15.

IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis.

Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, Verstegen NJM, Ciampricotti M, Hawinkels LJAC, Jonkers J, de Visser KE.

Nature. 2015 Jun 18;522(7556):345-348. doi: 10.1038/nature14282. Epub 2015 Mar 30.

16.

Morphine does not facilitate breast cancer progression in two preclinical mouse models for human invasive lobular and HER2⁺ breast cancer.

Doornebal CW, Vrijland K, Hau CS, Coffelt SB, Ciampricotti M, Jonkers J, de Visser KE, Hollmann MW.

Pain. 2015 Aug;156(8):1424-32. doi: 10.1097/j.pain.0000000000000136.

PMID:
25734987
17.

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.

Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, Jones T, Jucknischke U, Scheiblich S, Kaluza K, Gorr IH, Walz A, Abiraj K, Cassier PA, Sica A, Gomez-Roca C, de Visser KE, Italiano A, Le Tourneau C, Delord JP, Levitsky H, Blay JY, Rüttinger D.

Cancer Cell. 2014 Jun 16;25(6):846-59. doi: 10.1016/j.ccr.2014.05.016. Epub 2014 Jun 2.

18.

Cancer: Inflammation lights the way to metastasis.

Coffelt SB, de Visser KE.

Nature. 2014 Mar 6;507(7490):48-9. doi: 10.1038/nature13062. Epub 2014 Feb 26. No abstract available.

PMID:
24572360
19.

A preclinical mouse model of invasive lobular breast cancer metastasis.

Doornebal CW, Klarenbeek S, Braumuller TM, Klijn CN, Ciampricotti M, Hau CS, Hollmann MW, Jonkers J, de Visser KE.

Cancer Res. 2013 Jan 1;73(1):353-63. doi: 10.1158/0008-5472.CAN-11-4208. Epub 2012 Nov 14.

20.

Developmental stage-specific contribution of LGR5(+) cells to basal and luminal epithelial lineages in the postnatal mammary gland.

de Visser KE, Ciampricotti M, Michalak EM, Tan DW, Speksnijder EN, Hau CS, Clevers H, Barker N, Jonkers J.

J Pathol. 2012 Nov;228(3):300-9. doi: 10.1002/path.4096.

PMID:
22926799
21.

Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system.

Ciampricotti M, Hau CS, Doornebal CW, Jonkers J, de Visser KE.

Nat Med. 2012 Mar 6;18(3):344-6; author reply 346. doi: 10.1038/nm.2652. No abstract available.

PMID:
22395693
22.

Development of metastatic HER2(+) breast cancer is independent of the adaptive immune system.

Ciampricotti M, Vrijland K, Hau CS, Pemovska T, Doornebal CW, Speksnijder EN, Wartha K, Jonkers J, de Visser KE.

J Pathol. 2011 May;224(1):56-66. doi: 10.1002/path.2837. Epub 2011 Jan 17.

PMID:
21480230
23.

Retraction. The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation.

Ogink J, Kreike B, Nuyten D, de Visser KE, Roos E.

Cancer Res. 2011 Feb 1;71(3):1196. doi: 10.1158/0008-5472.CAN-10-4378. Epub 2011 Jan 18. No abstract available.

24.

Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer.

Vollebergh MA, Kappers I, Klomp HM, Buning-Kager JC, Korse CM, Hauptmann M, de Visser KE, van den Heuvel MM, Linn SC.

J Thorac Oncol. 2010 Dec;5(12):1939-48. doi: 10.1097/JTO.0b013e3181f77a39.

25.

FcRgamma activation regulates inflammation-associated squamous carcinogenesis.

Andreu P, Johansson M, Affara NI, Pucci F, Tan T, Junankar S, Korets L, Lam J, Tawfik D, DeNardo DG, Naldini L, de Visser KE, De Palma M, Coussens LM.

Cancer Cell. 2010 Feb 17;17(2):121-34. doi: 10.1016/j.ccr.2009.12.019. Epub 2010 Feb 4.

26.

A tissue reconstitution model to study cancer cell-intrinsic and -extrinsic factors in mammary tumourigenesis.

Evers B, Speksnijder EN, Schut E, Ciampricotti M, Smalley MJ, Derksen PW, Jonkers J, de Visser KE.

J Pathol. 2010 Jan;220(1):34-44. doi: 10.1002/path.2655.

PMID:
19927317
27.

Towards understanding the role of cancer-associated inflammation in chemoresistance.

de Visser KE, Jonkers J.

Curr Pharm Des. 2009;15(16):1844-53. Review.

PMID:
19519427
28.

Inflammation as target for pharmaceutical intervention in cancer.

Schiffelers RM, de Visser KE.

Curr Pharm Des. 2009;15(16):1822-4. No abstract available.

PMID:
19519425
29.

Approaches to determine expression of inflammatory cytokines.

Amsen D, de Visser KE, Town T.

Methods Mol Biol. 2009;511:107-42. doi: 10.1007/978-1-59745-447-6_5.

30.

A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer.

Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, Kok M, Teschendorff AE, Mook S, van 't Veer L, Caldas C, Salmon RJ, van de Vijver MJ, Wessels LF.

Breast Cancer Res. 2008;10(6):R93. doi: 10.1186/bcr2192. Epub 2008 Nov 13.

31.

The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation.

Meijer J, Ogink J, Kreike B, Nuyten D, de Visser KE, Roos E.

Cancer Res. 2008 Jun 15;68(12):4701-8. doi: 10.1158/0008-5472.CAN-08-0482. Retraction in: Ogink J, Kreike B, Nuyten D, de Visser KE, Roos E. Cancer Res. 2011 Feb 1;71(3):1196.

32.

Spontaneous immune responses to sporadic tumors: tumor-promoting, tumor-protective or both?

de Visser KE.

Cancer Immunol Immunother. 2008 Oct;57(10):1531-9. doi: 10.1007/s00262-008-0501-x. Epub 2008 Mar 15. Review.

PMID:
18343921
33.

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.

Rottenberg S, Nygren AO, Pajic M, van Leeuwen FW, van der Heijden I, van de Wetering K, Liu X, de Visser KE, Gilhuijs KG, van Tellingen O, Schouten JP, Jonkers J, Borst P.

Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12117-22. Epub 2007 Jul 11.

34.

Immune cells as anti-cancer therapeutic targets and tools.

Johansson M, Tan T, de Visser KE, Coussens LM.

J Cell Biochem. 2007 Jul 1;101(4):918-26. Review.

PMID:
17265430
35.

Analysis of immune cell infiltrates during squamous carcinoma development.

Junankar SR, Eichten A, Kramer A, de Visser KE, Coussens LM.

J Investig Dermatol Symp Proc. 2006 Sep;11(1):36-43.

36.

The inflammatory tumor microenvironment and its impact on cancer development.

de Visser KE, Coussens LM.

Contrib Microbiol. 2006;13:118-37. Review.

PMID:
16627962
37.

Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.

Overwijk WW, de Visser KE, Tirion FH, de Jong LA, Pols TW, van der Velden YU, van den Boorn JG, Keller AM, Buurman WA, Theoret MR, Blom B, Restifo NP, Kruisbeek AM, Kastelein RA, Haanen JB.

J Immunol. 2006 May 1;176(9):5213-22.

38.

Inflammation, proteases and cancer.

van Kempen LC, de Visser KE, Coussens LM.

Eur J Cancer. 2006 Apr;42(6):728-34. Epub 2006 Mar 9. Review.

PMID:
16524717
39.

Paradoxical roles of the immune system during cancer development.

de Visser KE, Eichten A, Coussens LM.

Nat Rev Cancer. 2006 Jan;6(1):24-37. Review.

PMID:
16397525
40.

De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent.

de Visser KE, Korets LV, Coussens LM.

Cancer Cell. 2005 May;7(5):411-23.

41.

The interplay between innate and adaptive immunity regulates cancer development.

de Visser KE, Coussens LM.

Cancer Immunol Immunother. 2005 Nov;54(11):1143-52. Epub 2005 May 12. Review.

PMID:
15889249
42.

Early neoplastic progression is complement independent.

de Visser KE, Korets LV, Coussens LM.

Neoplasia. 2004 Nov-Dec;6(6):768-76.

43.

The impact of self-tolerance on the polyclonal CD8+ T cell repertoire.

Kessels HW, de Visser KE, Tirion FH, Coccoris M, Kruisbeek AM, Schumacher TN.

J Immunol. 2004 Feb 15;172(4):2324-31.

44.

CD8+ T cell tolerance and cancer immunotherapy.

De Visser KE, Schumacher TN, Kruisbeek AM.

J Immunother. 2003 Jan-Feb;26(1):1-11. Review.

PMID:
12514424
45.

Circumventing T-cell tolerance to tumour antigens.

Kessels HW, de Visser KE, Kruisbeek AM, Schumacher TN.

Biologicals. 2001 Sep-Dec;29(3-4):277-83.

PMID:
11851328
46.

Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection?

Cordaro TA, de Visser KE, Tirion FH, Schumacher TN, Kruisbeek AM.

J Immunol. 2002 Jan 15;168(2):651-60.

47.

Low-avidity self-specific T cells display a pronounced expansion defect that can be overcome by altered peptide ligands.

de Visser KE, Cordaro TA, Kessels HW, Tirion FH, Schumacher TN, Kruisbeek AM.

J Immunol. 2001 Oct 1;167(7):3818-28.

48.

A murine model for the effects of pelvic radiation and cisplatin chemotherapy on human papillomavirus vaccine efficacy.

Small LA, Da Silva DM, de Visser KE, Velders MP, Fisher SG, Potkul RK, Kast WM.

Clin Cancer Res. 2001 Mar;7(3 Suppl):876s-881s.

PMID:
11300486
49.

Tracing and characterization of the low-avidity self-specific T cell repertoire.

de Visser KE, Cordaro TA, Kioussis D, Haanen JB, Schumacher TN, Kruisbeek AM.

Eur J Immunol. 2000 May;30(5):1458-68.

50.

Tumor size at the time of adoptive transfer determines whether tumor rejection occurs.

Cordaro TA, de Visser KE, Tirion FH, Graus YM, Haanen JB, Kioussis D, Kruisbeek AM.

Eur J Immunol. 2000 May;30(5):1297-307.

Supplemental Content

Loading ...
Support Center